Price
$0.2672
Increased by +0.04%
Dollar Volume (20D)
733.52 K
ADR%
11.65
Earnings Report Date (estimate)
Oct 6, 23 (N/A)
Market Cap.
5.12 M
Shares Float
18.97 M
Shares Outstanding
19.14 M
Beta
0.00
Price / Earnings
0.00
BPR
0.06
20D Range
0.25 0.46
50D Range
0.25 4.51
200D Range
0.25 81.90
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 11, 23 -4.43 -7.88
Increased by +5.56%
Mar 13, 23 -0.23 -0.42
Increased by +107.71%
Nov 14, 22 -0.68 -0.25
Decreased by -688.00%
Aug 22, 22 -0.52 -0.42
Decreased by -56.69%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0.00
Decreased by N/A%
-3.14 M
Decreased by -1.98%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-2.84 M
Increased by +69.47%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-5.04 M
Decreased by -685.70%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-4.66 M
Increased by +13.70%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-3.08 M
Increased by +0.16%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-9.29 M
Decreased by -7.71 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
860.00 K
Increased by +189.58%
Increased by +N/A%
Decreased by N/A%
Jun 30, 21 0.00 - -5.40 M -
Decreased by N/A%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.